InsidersTradesSigma
Track the Pulmonx Corp share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pulmonx Corp has logged 177 public disclosures. Market capitalisation: €51.5m. The latest transaction was disclosed on 9 June 2026 (Attribution). Among the most active insiders: French Glendon E. III. All data is accessible without an account.
177
Insider Decl.
n/a
Thresholds
€353,663
6 ops.
Buy Volume
€9m
114 ops.
Sell Volume
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,008 of 29,057 companies
18.4
score / 100
Value6
Quality31
FCF yld-32%
Earn yld-53%
EV/EBITDA·
ROE-89%
Gross mgn74%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 June 2026
Declarations177 total
40,000 shares0Common StockSEC:0001644557-26-000022:0
40,000 shares0Common StockSEC:0001402459-26-000002:0
40,000 shares0Common StockSEC:0001034413-26-000002:0
756 shares@ US$1.43100.0% of flowCommon StockSEC:0002098678-26-000001:0
2,708 shares@ US$1.430.1% of flowCommon StockSEC:0001805624-26-000001:0
835 shares@ US$1.430.0% of flowCommon StockSEC:0001804146-26-000001:0
1,163 shares@ US$1.431.6% of flowCommon StockSEC:0001354228-26-000002:0
23,321 shares@ US$1.9914.8% of flowCommon StockSEC:0001402459-25-000005:0
1,200,000 shares0Common StockSEC:0001670118-25-000006:0
2,524 shares@ US$1.570.1% of flowCommon StockSEC:0001805624-25-000005:0
683 shares@ US$1.570.0% of flowCommon StockSEC:0001804146-25-000004:0
976 shares@ US$1.571.5% of flowCommon StockSEC:0001354228-25-000006:0
5,118 shares@ US$1.602.4% of flowCommon StockSEC:0001415889-25-023574:0
4,271 shares@ US$1.605.1% of flowCommon StockSEC:0001415889-25-023573:0
707 shares@ US$1.600.0% of flowCommon StockSEC:0001415889-25-023572:0
929 shares@ US$1.601.5% of flowCommon StockSEC:0001415889-25-023571:0
8,000 shares@ US$3.1643.5% of flowCommon StockSEC:0001415889-25-017271:0
23,321 shares@ US$3.0627.2% of flowCommon StockSEC:0001415889-25-015859:0
Canonical exit: 3 Sept 2025 (T+90)
37,153 shares0Common StockSEC:0001415889-25-015652:0
37,153 shares0Common StockSEC:0001415889-25-015651:0
37,153 shares0Common StockSEC:0001415889-25-015649:0
37,153 shares0Common StockSEC:0001415889-25-015645:0
37,153 shares0Common StockSEC:0001415889-25-015644:0
37,153 shares0Common StockSEC:0001415889-25-015639:0
37,153 shares0Common StockSEC:0001415889-25-015636:0
25 of 177 declarations
关于 Pulmonx Corp
Pulmonx Corp.（股票代码：LUNG）是一家在美国纳斯达克市场上市的美国医疗技术公司。对于法国、比利时和瑞士投资者而言，该公司最好被视为一家专业呼吸护理企业，专注于严重肺气肿（一种衰弱性慢阻肺）的微创治疗。该公司成立于1995年，已围绕介入肺学建立了其业务框架，将治疗设备、患者选择工具和诊断/规划软件相结合，以支持医生在整个治疗路径中的工作。([stockanalysis.com](https://stockanalysis.com/stocks/lung/company/?utm_source=openai)) Pulmonx的商业核心是Zephyr支气管内膜瓣膜，这是一种可植入的支气管瓣膜，设计用于选定的严重肺气肿患者，这些患者尽管接受了医学管理但仍然症状严重，或不适合手术治疗。该公司还销售Chartis肺功能评估系统，该系统帮助临床医生评估气流并识别适当的靶区，以及LungTraX平台，这是一项基于云的定量CT分析服务，支持患者识别和手术规划。这使得Pulmonx不仅仅是一家单一设备公司：它是围绕患者筛查、医生培训和临床工作流整合构建的治疗赋能平台。([investors.pulmonx.com](https://investors.pulmonx.com/investor-faqs?utm_source=openai)) 从竞争角度来看，Pulmonx在介入肺学领域占据利基领导地位。其公开资料将该公司描述为肺部疾病微创治疗的全球领导者，在美国、欧洲、澳大利亚、亚洲、拉丁美洲和其他市场都有商业运营。公司总部位于加州红木城，该集团还在瑞士纳沙泰尔设有办事处。这种地理足迹很重要，因为Pulmonx在一个高度监管、对报销敏感的市场中运营，商业采用取决于医生教育、程序基础设施和本地市场准入。([craft.co](https://craft.co/pulmonx/locations?utm_source=openai)) 最近的发展集中在运营执行和财务报告上。Pulmonx发布了2025年全年业绩和2026年第一季度业绩，管理层将该时期描述为过渡期，并强调了重新调整美国销售组织和推进临床项目的行动。该公司还强调了Zephyr瓣膜手术的持续全球采用。对于投资者而言，这创造了一个典型的医疗技术概况：差异化技术具有有意义的长期临床机会，但也依赖于手术增长、报销动态、监管执行和商业化纪律。在美国纳斯达克上，Pulmonx仍然是一个专业医疗保健名称，具有明确的利基、国际足迹和与其肺容量减少平台采用相关的风险/收益概况。([investors.pulmonx.com](https://investors.pulmonx.com/news-releases/news-release-details/pulmonx-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
